Cadmium pollution, long-lasting inflammation, and airway disease

Environmental Cadmium, persistent inflammation and airways disease

NIH-funded research University of Alabama at Birmingham · NIH-11319016

This project looks at whether cadmium pollution causes ongoing lung inflammation and airway disease in people who live near contaminated sites like North Birmingham.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Alabama at Birmingham NIH-funded
Lab location1 site (Birmingham, United States)
Project IDNIH-11319016 on NIH RePORTER

What this research studies

If you live near the North Birmingham Superfund site, researchers will work with community members and use samples such as lung tissue and immune cells to measure cadmium levels. They will examine how cadmium alters alveolar macrophage function, including the cells' ability to clear dying cells (efferocytosis), and measure markers like PAD4 and citrullinated CaMKII. Lab experiments using human samples and experimental models will test the molecular steps that link cadmium exposure to persistent inflammation and airway remodeling. The team partners with the local Superfund Research Center to connect environmental exposure data with immune changes that could be targeted for treatment.

Who could benefit from this research

Good fit: Ideal participants are adults who live or have lived in cadmium-contaminated areas (for example the North Birmingham Superfund site) who have chronic airway symptoms or are willing to provide biological samples.

Not a fit: People whose airway disease is clearly due to non-environmental causes or who have no history of cadmium exposure are less likely to benefit from this work.

Why it matters

Potential benefit: If successful, this work could point to ways to reduce persistent lung inflammation and lower chronic airway disease in exposed communities.

How similar studies have performed: Past studies have linked cadmium exposure to lung disease and impaired macrophage function, but targeting PAD4 and citrullinated CaMKII in impaired efferocytosis is a relatively new approach.

Where this research is happening

Birmingham, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Airway Disease
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.